NDAINHALATION, INJECTIONSOLUTION
Lifecycle
Pre-Launch
Data completeness
1/8 — Limited
XENEISOL (xenon xe-133) by Lantheus Medical Imaging is radiopharmaceutical activity [moa].
Drug data last refreshed 4h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XENEISOL (Xenon Xe-133) is a radiopharmaceutical administered via inhalation or injection as a solution. It leverages radiopharmaceutical activity for diagnostic imaging purposes. The drug is intended for patients requiring ventilation or perfusion imaging to assess pulmonary and cardiac function.
Pre-Launch
Early-stage product with undefined commercial trajectory; brand team building phase may offer limited but foundational career growth opportunities.
Mechanism of Action
Radiopharmaceutical Activity
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on XENEISOL offers early-career opportunity to influence product launch in a specialized diagnostic imaging space with Lantheus Medical Imaging, a leader in radiopharmaceuticals. Limited current job openings suggest roles are concentrated in regulatory, manufacturing, and medical affairs functions during pre-launch phase.
Regulatory Affairs SpecialistManufacturing/Supply Chain
Worked on XENEISOL at Lantheus Medical Imaging? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.